Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management
- PMID: 15456328
- DOI: 10.2165/00003495-200464200-00003
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management
Abstract
Hyperprolactinaemia is an important but neglected adverse effect of antipsychotic medication. It occurs frequently with conventional antipsychotics and some atypical antipsychotics (risperidone and amisulpride) but is rare with other atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, ziprasidone). For this reason the terms 'prolactin-sparing' and 'prolactin-raising' are more useful than 'atypical' and 'conventional' when considering the effect of antipsychotic drugs on serum prolactin. During antipsychotic treatment prolactin levels can rise 10-fold or more above pretreatment values. In a recent study approximately 60% of women and 40% of men treated with a prolactin-raising antipsychotic had a prolactin level above the upper limit of the normal range. The distinction between asymptomatic and symptomatic hyperprolactinaemia is important but is often not made in the literature. Some symptoms of hyperprolactinaemia result from a direct effect of prolactin on target tissues but others result from hypogonadism caused by prolactin disrupting the normal functioning of the hypothalamic-pituitary-gonadal axis. Symptoms of hyperprolactinaemia include gynaecomastia, galactorrhoea, sexual dysfunction, infertility, oligomenorrhoea and amenorrhoea. These symptoms are little researched in psychiatric patients. Existing data suggest that they are common but that clinicians underestimate their prevalence. For example, well conducted studies of women treated with conventional antipsychotics have reported prevalence rates of approximately 45% for oligomenorrhoea/amenorrhoea and 19% for galactorrhoea. An illness-related under-function of the hypothalamic-pituitary-gonadal axis in female patients with schizophrenia may also contribute to menstrual irregularities. Long-term consequences of antipsychotic-related hypogonadism require further research but are likely and include premature bone loss in men and women. There are conflicting data on whether hyperprolactinaemia is associated with an increased risk of breast cancer in women. In patients prescribed antipsychotics who have biochemically confirmed hyperprolactinaemia it is important to exclude other causes of prolactin elevation, in particular tumours in the hypothalamic-pituitary area. If a patient has been amenorrhoeic for 1 year or more, investigations should include bone mineral density measurements. Management should be tailored to the individual patient. Options include reducing the dose of the antipsychotic, switching to a prolactin-sparing agent, prescribing a dopamine receptor agonist and prescribing estrogen replacement in hypoestrogenic female patients. The efficacy and risks of the last two treatment options have not been systematically examined. Antipsychotic-induced hyperprolactinaemia should become a focus of interest in the drug treatment of psychiatric patients, particularly given the recent introduction of prolactin-sparing antipsychotics. Appropriate investigations and effective management should reduce the burden of adverse effects and prevent long-term consequences.
Copyright 2004 Adis Data Information BV
Similar articles
-
[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Encephale. 2014. PMID: 23928066 Review. French.
-
[Hyperprolactinemia in mentally ill patients].Acta Med Port. 2011 Nov-Dec;24(6):1005-12. Epub 2012 Feb 20. Acta Med Port. 2011. PMID: 22713195 Review. Portuguese.
-
Prolactin awareness: an essential consideration for physical health in schizophrenia.Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Eur Neuropsychopharmacol. 2008. PMID: 18346598 Review.
-
Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5. doi: 10.1177/0269881107088439. J Psychopharmacol. 2008. PMID: 18477623 Review.
-
Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.Br J Psychiatry. 2003 Mar;182:199-204. doi: 10.1192/bjp.182.3.199. Br J Psychiatry. 2003. PMID: 12611781 Review.
Cited by
-
Significance of Duodenal Prolactin Receptor Modulation by Calcium and Vitamin D in Sulpiride-Induced Hyperprolactinemia.Medicina (Kaunas). 2024 Jun 4;60(6):942. doi: 10.3390/medicina60060942. Medicina (Kaunas). 2024. PMID: 38929559 Free PMC article.
-
Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri.S Afr J Psychiatr. 2024 Feb 1;30:2133. doi: 10.4102/sajpsychiatry.v30i0.2133. eCollection 2024. S Afr J Psychiatr. 2024. PMID: 38444408 Free PMC article.
-
Methadone Withdrawal-Related Psychosis in a Patient With Hormone-Dependent Breast Cancer: A Case Report.Cureus. 2023 Dec 28;15(12):e51240. doi: 10.7759/cureus.51240. eCollection 2023 Dec. Cureus. 2023. PMID: 38283524 Free PMC article.
-
The effect of antipsychotic medication and the associated hyperprolactinemia as a risk factor for periodontal diseases in schizophrenic patients: a cohort retrospective study.BMC Oral Health. 2023 Oct 24;23(1):786. doi: 10.1186/s12903-023-03404-1. BMC Oral Health. 2023. PMID: 37875841 Free PMC article.
-
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.Curr Psychiatry Rep. 2023 Nov;25(11):723-733. doi: 10.1007/s11920-023-01460-6. Epub 2023 Oct 21. Curr Psychiatry Rep. 2023. PMID: 37864676 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical